false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP06.06. Plasma Extracellular Vesicle miR-10b-5p a ...
EP06.06. Plasma Extracellular Vesicle miR-10b-5p as a Biomarker for Progressivity, Survivorship and Treatment Response in NSCLC Patients - PDF(Abstract)
Back to course
Pdf Summary
This study aimed to investigate the role of miR-10b-5p as a biomarker for progressivity, survivorship, and treatment response in non-small cell lung cancer (NSCLC) patients. The authors collected serum samples from 16 NSCLC patients and measured the expression levels of miR-10b-5p before and after treatment. They found that the expression of miR-10b-5p was significantly increased in patients with stable disease and progressive disease groups, while it decreased in the partial response group. The authors also observed that the expression of miR-10b-5p after therapy was significantly higher than before therapy in the stable disease and progressive disease groups. However, there was no significant correlation between miR-10b-5p expression and overall survival or progression-free survival. <br /><br />This study highlights the potential of miR-10b-5p as a molecular biomarker for assessing the therapeutic response in NSCLC patients. These findings suggest that monitoring the changes in miR-10b-5p expression levels could provide valuable information about the effectiveness of treatment in NSCLC patients. However, further research is needed to determine the predictive value of miR-10b-5p expression for overall survival and progression-free survival in lung cancer patients. Overall, this study contributes to the understanding of the role of miR-10b-5p in NSCLC and its potential as a biomarker for treatment response.
Asset Subtitle
Jaka Pradipta
Meta Tag
Speaker
Jaka Pradipta
Topic
Pathology & Biomarkers: Prognostic Biomarkers
Keywords
miR-10b-5p
biomarker
progressivity
survivorship
treatment response
non-small cell lung cancer
NSCLC
serum samples
expression levels
therapeutic response
×
Please select your language
1
English